Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.
The following Management’s Discussion and Analysis of Financial Condition and Results of Operations is intended to provide information necessary to understand our consolidated financial statements for the three and nine months ended September 30, 2024 and 2023 included elsewhere in this Report, and highlight certain other information which, in the opinion of management, will enhance a reader’s understanding of our financial condition, changes in financial condition and results of operations. These historical consolidated financial statements may not be indicative of our future performance. This Management’s Discussion and Analysis of Financial Condition and Results of Operations contains a number of forward-looking statements, all of which are based on our current expectations and could be affected by the uncertainties and risks described throughout this filing, particularly under Risk Factors in this Report and those Risk Factors in Part I, Item 1A of our most recent Annual Report on Form 10-K for the year ended December 31, 2023 as filed with the SEC. For additional information, refer to the section above entitled “Cautionary Note Regarding Forward-Looking Statements.”
Overview
We are a diagnostics technology company. Our tests are designed to help provide clarity and confidence to physicians and their patients. VitaGraft™ is a clinical blood-based solid organ transplantation monitoring test, GraftAssure™ is a RUO blood-based donor-derived cell-free DNA test, DetermaIO™ is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies, and the pipeline test DetermaCNI™ is a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients.
Our mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes.
We do this primarily by developing molecular diagnostic test kits that empower our customers to run their own tests to participate in the patient care value chain, which is counter-positioned with the central laboratory model. Our decentralized approach also puts testing in the hands of researchers to enable more studies, which inspires innovation, which can improve standards of care while also creating demand for more testing. We develop tests that measure both established biomarkers as well as pioneer the adoption of new and more effective biomarkers.
We believe that combining innovative science with a simple, but disruptive, business model can create enormous value. This model is designed to empower doctors to reduce uncertainty to make better decisions to save lives as well as enable researchers to measure biomarkers to inspire innovation.
Our customer institutions are hospitals, transplant centers, and labs. The decision to deploy our tests on behalf of patients or research studies comes from front line doctors, including surgeons, nephrologists and oncologists, as well as researchers, pathologists, lab directors, medical directors, department heads, lab managers, and chief medical officers.
Our operating premise is that democratizing access to testing to foster scientific innovation and better treatments ultimately reduces the cost of care, while expanding access and improving outcomes.
At the heart, we are a science-driven organization that champions scientific integrity and inquiry. We employ world-renowned scientists who generate intellectual property in our strategic target markets. We have built and acquired an intellectual property portfolio that we believe will enable us to gain share in well-established clinical and research markets.
Our primary near-term strategic market is organ transplant. Oncocyte’s molecular diagnostic tests are designed to help the industry to better address one of the leading challenges in the transplantation market – which is the body’s potential to reject the donor organ. We do this by detecting early evidence of graft organ damage in the blood through assessing a known biomarker known as donor-derived cell-free DNA. VitaGraft Kidney, for example, can find donor kidney damage up to 10 months sooner than other protocols. VitaGraft is analytically and clinically validated in three major solid organ transplant types (kidney, liver and heart) by peer reviewed international publications. We received a positive coverage decision from MolDx for VitaGraft Kidney in August of 2023, and it became commercially available for ordering in January 2024 through our CLIA Laboratory in Nashville, Tennessee. VitaGraft Kidney is now broadly available to transplant professionals upon request.
In July 2024, we began to commercialize the technology underlying VitaGraft Kidney by distributing its sister product, GraftAssure, which is intended to be sold and used for research purposes and is labeled as RUO. We expect to distribute our RUO production through a mix of direct sales, partnering and distribution agreements, and licensing. We have entered into an agreement with Bio-Rad, our global strategic partner, to collaborate in the development and the commercialization of RUO and IVD kitted transplant products (see Note 10, “Collaborative Arrangements,” to our consolidated financial statements included elsewhere in this Report for additional information).
Under strict regulatory rules, our tests may not be used in a clinical treatment setting until they have attained IVD approval from the Food and Drug Administration (“FDA”) in the U.S. and In Vitro Diagnostic Medical Devices Regulation approval in the European Union. As such, we are working with these regulatory bodies to attain such approval, supporting future distribution and higher sales of our products for clinical use.
We also have a laboratory and pharma services lab, certified under the CLIA and accredited by the Collage of American Pathologists, in Nashville, Tennessee, and a research and development lab in Göttingen, Germany. Our innovation centers in Nashville and Germany employ world-renowned research scientists who are leaders in their field.
Our secondary strategic market is in the field of oncology – namely through diagnostic tests that can measure and predict which patients will best respond to certain types of therapies, as well as provide efficacy monitoring for therapies. For example, we are continuing to develop DetermaIO, a test with promising data supporting its potential to help identify patients likely to respond to checkpoint inhibitor drugs. This new class of drugs modulate the immune response and show activity in multiple solid tumor types including non-small cell lung cancer, and triple negative breast cancer. DetermaIO is currently available as part of an early access program with leaders in the immuno-oncology field. A kitted research product format of the underlying technology began proof-of-concept development in 2023. The application of immunotherapy is a global problem, so we expect partnering opportunities for each of our products as they reach clinical maturity. We also expect to begin commercializing our oncology product line, which includes DetermaIO, over the next 18 months.
We also perform other assay development and clinical testing services for pharmaceutical and biotechnology companies through our Pharma Services operations.
The inherent uncertainties of developing and commercializing new diagnostic tests for medical use make it impossible to predict the amount of time and expense that will be required to complete the development and commercialization of those tests. There is no assurance that we will be successful in developing new technology or diagnostic tests, nor that any technology or diagnostic tests that we may develop will be proven safe and effective in diagnosis of cancer in humans or will be successfully commercialized. We expect that our operating expenses will continue to increase if we successfully complete the development of DetermaIO and commercialize this test.
Recent Developments
Collaboration Agreement
On April 5, 2024, we entered into an agreement with Bio-Rad, our global strategic partner, to collaborate in the development and the commercialization of RUO and IVD kitted transplant products. On November 8, 2024, Oncocyte and Bio-Rad entered into a memorandum of understanding with respect to such agreement to establish additional activities to be performed by each party pursuant to such agreement. See Note 10, “Collaborative Arrangements,” to our consolidated financial statements included elsewhere in this Report for additional information.
April 2024 Offering
On April 15, 2024, we consummated the April 2024 Offering. The gross proceeds from the April 2024 Offering were approximately $15.8 million. See Note 7, “Common Stock – April 2024 Offering,” to our consolidated financial statements included elsewhere in this Report for additional information.
August 2024 Offering
On August 9, 2024, we entered into a sales agreement with a sales agent, pursuant to which the Company may offer and sell from time to time up to an aggregate of $7.5 million of shares of our common stock, through the sales agent through an at-the-market facility. As of September 30, 2024, we received net proceeds from the sale of such shares of approximately $17,000. See Note 7, “Common Stock – August 2024 Offering,” to our consolidated financial statements included elsewhere in this Report for additional information.
October 2024 Offering
On October 4, 2024, we consummated the October 2024 Offering. The gross proceeds from the October 2024 Offering were approximately $10.2 million. See Note 12, “Subsequent Events,” to our consolidated financial statements included elsewhere in this Report for additional information.
Results of Operations
Summary Results of Operations
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
September 30, |
|
|
Nine Months Ended
September 30, |
|
|
|
2024 |
|
|
2023 |
|
|
$ Change |
|
|
% Change |
|
|
2024 |
|
|
2023 |
|
|
$ Change |
|
|
% Change |
|
|
|
(In thousands, except percentage change values) |
|
Net revenue |
|
$ |
115 |
|
|
$ |
429 |
|
|
$ |
(314 |
) |
|
|
(73 |
)% |
|
$ |
395 |
|
|
$ |
1,189 |
|
|
$ |
(794 |
) |
|
|
(67 |
)% |
Cost of revenues |
|
|
43 |
|
|
|
159 |
|
|
|
(116 |
) |
|
|
(73 |
)% |
|
|
184 |
|
|
|
593 |
|
|
|
(409 |
) |
|
|
(69 |
)% |
Cost of revenues – amortization of acquired intangibles |
|
|
22 |
|
|
|
22 |
|
|
|
— |
|
|
|
— |
|
|
|
66 |
|
|
|
66 |
|
|
|
— |
|
|
|
— |
|
Research and development |
|
|
2,817 |
|
|
|
2,185 |
|
|
|
632 |
|
|
|
29 |
% |
|
|
7,582 |
|
|
|
6,747 |
|
|
|
835 |
|
|
|
12 |
% |
Sales and marketing |
|
|
1,043 |
|
|
|
713 |
|
|
|
330 |
|
|
|
46 |
% |
|
|
2,742 |
|
|
|
2,213 |
|
|
|
529 |
|
|
|
24 |
% |
General and administrative |
|
|
2,565 |
|
|
|
2,487 |
|
|
|
78 |
|
|
|
3 |
% |
|
|
7,645 |
|
|
|
9,430 |
|
|
|
(1,785 |
) |
|
|
(19 |
)% |
Change in fair value of contingent consideration |
|
|
7,140 |
|
|
|
(435 |
) |
|
|
7,575 |
|
|
|
(1741 |
)% |
|
|
9,421 |
|
|
|
(16,947 |
) |
|
|
26,368 |
|
|
|
(156 |
)% |
Impairment losses |
|
|
— |
|
|
|
1,811 |
|
|
|
(1,811 |
) |
|
|
(100 |
)% |
|
|
— |
|
|
|
6,761 |
|
|
|
(6,761 |
) |
|
|
(100 |
)% |
Impairment loss on held for sale assets |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
169 |
|
|
|
1,283 |
|
|
|
(1,114 |
) |
|
|
(87 |
)% |
Loss from operations |
|
|
(13,515 |
) |
|
|
(6,513 |
) |
|
|
(7,002 |
) |
|
|
108 |
% |
|
|
(27,414 |
) |
|
|
(8,957 |
) |
|
|
(18,457 |
) |
|
|
206 |
% |
Total other income, net |
|
|
22 |
|
|
|
24 |
|
|
|
(2 |
) |
|
|
(8 |
)% |
|
|
262 |
|
|
|
94 |
|
|
|
168 |
|
|
|
179 |
% |
Loss from continuing operations |
|
|
(13,493 |
) |
|
|
(6,489 |
) |
|
|
(7,004 |
) |
|
|
108 |
% |
|
|
(27,152 |
) |
|
|
(8,863 |
) |
|
|
(18,289 |
) |
|
|
206 |
% |
Loss from discontinued operations (Note 11) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(2,926 |
) |
|
|
2,926 |
|
|
|
(100 |
)% |
Net loss |
|
$ |
(13,493 |
) |
|
$ |
(6,489 |
) |
|
$ |
(7,004 |
) |
|
|
108 |
% |
|
$ |
(27,152 |
) |
|
$ |
(11,789 |
) |
|
$ |
(15,363 |
) |
|
|
130 |
% |
Results of Operations – Three Months Ended September 30, 2024 Compared with the Three Months Ended September 30, 2023
Revenues decreased to $115,000 for the three months ended September 30, 2024, as compared to $429,000 in the prior period. Decreased revenues in Pharma Services are the result of our shift in strategic focus on commercializing our transplant kitted tests, and deploying our sales personnel toward signing new hospital research laboratory customers.
Loss from continuing operations was $13.5 million for the three months ended September 30, 2024, compared to $6.5 million for the comparable prior period. The loss from continuing operations expanded by $7.0 million mainly due to the change in fair value of contingent consideration, and the changes in Pharma Services revenue, operating expenses and other income and expenses from continuing operations as follows:
•Pharma Services revenue decreased by $308,000 due to a decreased number of contracts performed during the period. See below for additional information.
•Cost of revenues decreased by $116,000, primarily related to labor and allocated overhead associated with performing our Pharma Services. See below for additional information.
•Cost of revenues - amortization of acquired intangibles was unchanged, and relates to noncash amortization of acquired intangible assets such as our customer relationship intangible assets acquired as part of the Insight merger.
•Research and development expenses increased by $632,000, as we continue development of VitaGraft, DetermaIO and DetermaCNI. The main drivers of the increase were laboratory costs, facilities costs and personnel-related expenses, partially offset by depreciation and amortization, and stock-based compensation (see below for additional details).
•Sales and marketing expenses increased by $330,000, primarily attributable to continued ramp in sales, marketing and advertising activities related to the transplant business, as well as supporting the commercialization efforts within oncology. The main drivers of the increase were personnel-related expenses and other sales and marketing related expenses, partially offset by stock-based compensation (see below for additional details).
•General and administrative expenses increased by $78,000, primarily due to an increase in personnel-related expenses, partially offset by facilities costs and stock-based compensation. See below for additional details.
•Change in fair value of contingent consideration was a loss of $7.1 million in 2024 compared to a gain of $435,000 in 2023. This change was due to changes in the fair value model inputs and revised estimates on if and when future payouts will occur. The change is also driven by the Chronix Merger Agreement amendment during the first quarter of 2023, which provided superseding earnout consideration (see Note 3 to our consolidated financial statements included elsewhere in this Report). See below for additional information.
•The prior year impairment loss related to an asset impairment charge to leasehold improvements of $1.8 million (see Note 4 to our consolidated financial statements included elsewhere in this Report).
•Total other income, net decreased by $2,000, primarily due to reduced interest income and miscellaneous income in 2024 compared to 2023. See below for additional information.
Results of Operations – Nine Months Ended September 30, 2024 Compared with the Nine Months Ended September 30, 2023
Revenues decreased to $395,000 for the nine months ended September 30, 2024, as compared to $1.2 million in the prior period. Decreased revenues in Pharma Services are the result of our shift in strategic focus on commercializing our transplant kitted tests, and deploying our sales personnel toward signing new hospital research laboratory customers.
Loss from continuing operations was $27.2 million for the nine months ended September 30, 2024, compared to $8.9 million for the comparable prior period. The loss from continuing operations expanded by $18.3 million mainly due to the change in fair value of contingent consideration, and the changes in Pharma Services revenue, operating expenses and other income and expenses from continuing operations as follows:
•Pharma Services revenue decreased by $787,000 due to a decreased number of contracts performed during the period. See below for additional information.
•Cost of revenues decreased by $409,000, primarily related to labor and allocated overhead associated with performing our Pharma Services. See below for additional information.
•Cost of revenues - amortization of acquired intangibles was unchanged, and relates to noncash amortization of acquired intangible assets such as our customer relationship intangible assets acquired as part of the Insight merger.
•Research and development expenses increased by $835,000, as we continue development of VitaGraft, DetermaIO and DetermaCNI. The main drivers of the increase were personnel-related expenses, laboratory costs, facilities costs and professional fees, partially offset by depreciation and amortization, stock-based compensation and severance costs (see below for additional details).
•Sales and marketing expenses increased by $529,000, primarily attributable to continued ramp in sales, marketing and advertising activities related to the transplant business, as well as supporting the commercialization efforts within oncology. The main drivers of the increase were personnel-related expenses and other sales and marketing related expenses, partially offset by facilities costs and stock-based compensation (see below for additional details).
•General and administrative expenses decreased by $1.8 million, primarily due to decreases in stock-based compensation, severance costs, facilities costs and professional fees, partially offset by personnel-related expenses. See below for additional details.
•Change in fair value of contingent consideration was a loss of $9.4 million in 2024 compared to a gain of $16.9 million in 2023. This change was due to changes in the fair value model inputs and revised estimates on if and when future payouts will occur. The change is also driven by the Chronix Merger Agreement amendment during the first quarter of 2023, which provided superseding earnout consideration (see Note 3 to our consolidated financial statements included elsewhere in this Report). See below for additional information.
•The prior year impairment losses related to two asset impairments, including in-process research and development intangible assets of $5.0 million (see Note 5 to our consolidated financial statements included elsewhere in this Report) and leasehold improvements of $1.8 million (see Note 4 to our consolidated financial statements included elsewhere in this Report).
•Impairment loss on held for sale assets relates to various agreements to sell laboratory equipment and the subsequent fair value adjustments. See Note 2, “Assets Held for Sale and Discontinued Operations,” to our consolidated financial statements included elsewhere in this Report for additional information.
•Total other income, net increased by $168,000, primarily due to additional interest income and miscellaneous income in 2024 compared to 2023. See below for additional information.
Revenues
The following table shows our service revenues:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
September 30, |
|
|
Nine Months Ended
September 30, |
|
|
|
2024 |
|
|
2023 |
|
|
$ Change |
|
|
% Change |
|
|
2024 |
|
|
2023 |
|
|
$ Change |
|
|
% Change |
|
|
|
(In thousands, except percentage change values) |
|
Pharma Services |
|
$ |
115 |
|
|
$ |
423 |
|
|
$ |
(308 |
) |
|
|
(73 |
)% |
|
$ |
373 |
|
|
$ |
1,160 |
|
|
$ |
(787 |
) |
|
|
(68 |
)% |
Laboratory Developed Test Services |
|
|
— |
|
|
|
6 |
|
|
|
(6 |
) |
|
|
(100 |
)% |
|
|
22 |
|
|
|
29 |
|
|
|
(7 |
) |
|
|
(24 |
)% |
Total |
|
$ |
115 |
|
|
$ |
429 |
|
|
$ |
(314 |
) |
|
|
(73 |
)% |
|
$ |
395 |
|
|
$ |
1,189 |
|
|
$ |
(794 |
) |
|
|
(67 |
)% |
Pharma Services are generally performed on a time and materials basis. Upon our completion of the service to the customer in accordance with the contract, we have the right to bill the customer for the agreed upon price (either on a per test or per deliverable basis) and recognize the Pharma Services revenue at that time, on an accrual basis. Pharma Services revenues are generated under discrete agreements for particular customer projects that generally expire with the completion or termination of the customer’s project. Accordingly, different customers may account for greater or lesser portions of Pharma Services during different accounting periods, and Pharma Services revenues may exhibit a larger variance from accounting period to accounting period than other revenues such as Laboratory Developed Test Services revenue. Refer to Note 2, “Revenue Recognition – Pharma Services Revenue” and “Disaggregation of Revenues and Concentrations of Credit Risk,” to our consolidated financial statements included elsewhere in this Report for additional information.
Laboratory Developed Test Services generally relate to payments received from sales prior to the Razor Sale Transaction. We generated revenue from performing DetermaRx tests on clinical samples through orders received from physicians, hospitals, and other healthcare providers. For all payers other than Medicare, we must consider the novelty of the test, the uncertainty of receiving payment, or being subject to claims for a refund, from payers with whom it does not have a sufficient payment collection history or contractual reimbursement agreements. Accordingly, for those payers, we have recognized revenue upon payment. Refer to Note 2, “Revenue Recognition – Laboratory Developed Test Services,” to our consolidated financial statements included elsewhere in this Report for additional information.
Cost of Revenues
Cost of revenues generally consists of cost of materials, direct labor including payroll, payroll taxes, bonus, benefit and stock-based compensation, equipment and infrastructure expenses, clinical sample costs associated with performing Pharma Services, and amortization of acquired intangible assets. Infrastructure expenses include depreciation of laboratory equipment, allocated rent costs and leasehold improvements. Cost of revenues for Pharma Services varies depending on the nature, timing, and scope of customer projects.
Research and Development Expenses
A summary of the main drivers of the change in research and development expenses is as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
September 30, |
|
|
Nine Months Ended
September 30, |
|
|
|
2024 |
|
|
2023 |
|
|
$ Change |
|
|
% Change |
|
|
2024 |
|
|
2023 |
|
|
$ Change |
|
|
% Change |
|
|
|
(In thousands, except percentage change values) |
|
Personnel-related expenses |
|
$ |
1,080 |
|
|
$ |
886 |
|
|
$ |
194 |
|
|
|
22 |
% |
|
$ |
3,462 |
|
|
$ |
2,813 |
|
|
$ |
649 |
|
|
|
23 |
% |
Depreciation and amortization |
|
|
234 |
|
|
|
321 |
|
|
|
(87 |
) |
|
|
(27 |
)% |
|
|
706 |
|
|
|
1,036 |
|
|
|
(330 |
) |
|
|
(32 |
)% |
Stock-based compensation |
|
|
198 |
|
|
|
294 |
|
|
|
(96 |
) |
|
|
(33 |
)% |
|
|
607 |
|
|
|
926 |
|
|
|
(319 |
) |
|
|
(34 |
)% |
Laboratory supplies and expenses |
|
|
681 |
|
|
|
380 |
|
|
|
301 |
|
|
|
79 |
% |
|
|
1,483 |
|
|
|
955 |
|
|
|
528 |
|
|
|
55 |
% |
Facilities and insurance |
|
|
513 |
|
|
|
217 |
|
|
|
296 |
|
|
|
136 |
% |
|
|
893 |
|
|
|
529 |
|
|
|
364 |
|
|
|
69 |
% |
Professional fees, legal, and outside services |
|
|
121 |
|
|
|
91 |
|
|
|
30 |
|
|
|
33 |
% |
|
|
390 |
|
|
|
259 |
|
|
|
131 |
|
|
|
51 |
% |
Severance |
|
|
— |
|
|
|
(7 |
) |
|
|
7 |
|
|
|
(100 |
)% |
|
|
— |
|
|
|
152 |
|
|
|
(152 |
) |
|
|
(100 |
)% |
Other |
|
|
(10 |
) |
|
|
8 |
|
|
|
(18 |
) |
|
|
(225 |
)% |
|
|
39 |
|
|
|
49 |
|
|
|
(10 |
) |
|
|
(20 |
)% |
Clinical trials |
|
|
— |
|
|
|
(5 |
) |
|
|
5 |
|
|
|
(100 |
)% |
|
|
2 |
|
|
|
28 |
|
|
|
(26 |
) |
|
|
(93 |
)% |
Total |
|
$ |
2,817 |
|
|
$ |
2,185 |
|
|
$ |
632 |
|
|
|
29 |
% |
|
$ |
7,582 |
|
|
$ |
6,747 |
|
|
$ |
835 |
|
|
|
12 |
% |
% of Net Revenue |
|
|
2450 |
% |
|
|
509 |
% |
|
|
|
|
|
1940 |
% |
|
|
1919 |
% |
|
|
567 |
% |
|
|
|
|
|
1352 |
% |
We expect to continue to incur a significant amount of research and development expenses during the foreseeable future. We will continue development of VitaGraft, DetermaIO and DetermaCNI. Our future research and development efforts and expenses will also depend on the amount of capital that we are able to raise to finance those activities and whether we acquire rights to any new diagnostic tests. A portion of our costs for leasing and operating our CLIA laboratory in Tennessee, and in Germany with Chronix, will also be included in research and development expenses to the extent allocated to the development of our diagnostic tests.
We may commence clinical trials of DetermaIO if we develop that diagnostic test to the point where we determine that its use as a clinical diagnostic appears to be feasible.
Sales and Marketing Expenses
A summary of the main drivers of the change in sales and marketing expenses is as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
September 30, |
|
|
Nine Months Ended
September 30, |
|
|
|
2024 |
|
|
2023 |
|
|
$ Change |
|
|
% Change |
|
|
2024 |
|
|
2023 |
|
|
$ Change |
|
|
% Change |
|
|
|
(In thousands, except percentage change values) |
|
Personnel-related expenses |
|
$ |
703 |
|
|
$ |
486 |
|
|
$ |
217 |
|
|
|
45 |
% |
|
$ |
1,918 |
|
|
$ |
1,494 |
|
|
$ |
424 |
|
|
|
28 |
% |
Stock-based compensation |
|
|
44 |
|
|
|
64 |
|
|
|
(20 |
) |
|
|
(31 |
)% |
|
|
127 |
|
|
|
203 |
|
|
|
(76 |
) |
|
|
(37 |
)% |
Facilities and insurance |
|
|
79 |
|
|
|
58 |
|
|
|
21 |
|
|
|
36 |
% |
|
|
128 |
|
|
|
174 |
|
|
|
(46 |
) |
|
|
(26 |
)% |
Professional fees, legal, and outside services |
|
|
45 |
|
|
|
28 |
|
|
|
17 |
|
|
|
61 |
% |
|
|
166 |
|
|
|
140 |
|
|
|
26 |
|
|
|
19 |
% |
Marketing & Advertising |
|
|
41 |
|
|
|
44 |
|
|
|
(3 |
) |
|
|
(7 |
)% |
|
|
123 |
|
|
|
107 |
|
|
|
16 |
|
|
|
15 |
% |
Other |
|
|
131 |
|
|
|
33 |
|
|
|
98 |
|
|
|
297 |
% |
|
|
280 |
|
|
|
95 |
|
|
|
185 |
|
|
|
195 |
% |
Total |
|
$ |
1,043 |
|
|
$ |
713 |
|
|
$ |
330 |
|
|
|
46 |
% |
|
$ |
2,742 |
|
|
$ |
2,213 |
|
|
$ |
529 |
|
|
|
24 |
% |
% of Net Revenue |
|
|
907 |
% |
|
|
166 |
% |
|
|
|
|
|
741 |
% |
|
|
694 |
% |
|
|
186 |
% |
|
|
|
|
|
508 |
% |
We expect to continue to incur sales and marketing expenses during the foreseeable future as we complete product development and begin commercialization efforts for DetermaIO as a clinical test. Sales and marketing expenses will also increase if we successfully develop and begin commercializing VitaGraft and DetermaCNI, or if we acquire and commercialize other diagnostic tests. Our commercialization efforts and expenses will also depend on the amount of capital that we are able to raise to finance commercialization of our tests. Our future expenditures on sales and marketing will also depend on the amount of revenue that those efforts are likely to generate. Because physicians are more likely to prescribe a test for their patients if the cost is covered by Medicare or health insurance, demand for our diagnostic and other tests and our expenditures on sales and marketing are likely to increase if our diagnostic or other tests qualify for reimbursement by Medicare or private health insurance companies.
General and Administrative Expenses
A summary of the main drivers of the change in general and administrative expenses is as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
September 30, |
|
|
Nine Months Ended
September 30, |
|
|
|
2024 |
|
|
2023 |
|
|
$ Change |
|
|
% Change |
|
|
2024 |
|
|
2023 |
|
|
$ Change |
|
|
% Change |
|
|
|
(In thousands, except percentage change values) |
|
Personnel-related expenses and board fees |
|
$ |
1,078 |
|
|
$ |
756 |
|
|
$ |
322 |
|
|
|
43 |
% |
|
$ |
2,995 |
|
|
$ |
2,846 |
|
|
$ |
149 |
|
|
|
5 |
% |
Professional fees, legal, and outside services |
|
|
735 |
|
|
|
774 |
|
|
|
(39 |
) |
|
|
(5 |
)% |
|
|
2,473 |
|
|
|
2,720 |
|
|
|
(247 |
) |
|
|
(9 |
)% |
Facilities and insurance |
|
|
410 |
|
|
|
572 |
|
|
|
(162 |
) |
|
|
(28 |
)% |
|
|
1,235 |
|
|
|
1,791 |
|
|
|
(556 |
) |
|
|
(31 |
)% |
Stock-based compensation |
|
|
206 |
|
|
|
252 |
|
|
|
(46 |
) |
|
|
(18 |
)% |
|
|
520 |
|
|
|
1,119 |
|
|
|
(599 |
) |
|
|
(54 |
)% |
Severance |
|
|
— |
|
|
|
17 |
|
|
|
(17 |
) |
|
|
(100 |
)% |
|
|
— |
|
|
|
498 |
|
|
|
(498 |
) |
|
|
(100 |
)% |
Other |
|
|
136 |
|
|
|
116 |
|
|
|
20 |
|
|
|
17 |
% |
|
|
422 |
|
|
|
456 |
|
|
|
(34 |
) |
|
|
(7 |
)% |
Total |
|
$ |
2,565 |
|
|
$ |
2,487 |
|
|
$ |
78 |
|
|
|
3 |
% |
|
$ |
7,645 |
|
|
$ |
9,430 |
|
|
$ |
(1,785 |
) |
|
|
(19 |
)% |
% of Net Revenue |
|
|
2230 |
% |
|
|
580 |
% |
|
|
|
|
|
1651 |
% |
|
|
1935 |
% |
|
|
793 |
% |
|
|
|
|
|
1142 |
% |
Change in Fair Value of Contingent Consideration
We will pay contingent consideration if various payment milestones are triggered under the merger agreements through which we acquired Insight and Chronix. See Note 3 to our consolidated financial statements included elsewhere in this Report. Changes in the fair value of the contingent consideration will be based on our reassessment of the key assumptions underlying the determination of this liability as changes in circumstances and conditions occur from the Insight and Chronix acquisition dates to the reporting periods being presented, with the subsequent changes in fair value recorded as part of our consolidated results from operations for such periods. See above change explanation for additional information.
Other Income and Expenses
Other income and expenses are primarily comprised of interest income and expense, and unrealized gains/losses from marketable equity securities, which were sold in 2023 (see Note 2, “Marketable Equity Securities,” to our consolidated financial statements included elsewhere in this Report). Interest income is earned from money market funds we hold for capital preservation. Interest expense was incurred mainly from our financing lease obligations (see Note 6) and insurance financing activity.
Income Taxes
We did not record any provision or benefit for income taxes for the three and nine months ended September 30, 2024 and 2023, as we had a full valuation allowance for the periods presented (see Note 2 to our consolidated financial statements included elsewhere in this Report).
A valuation allowance is provided when it is more-likely-than-not that some portion of the deferred tax assets will not be realized. We established a full valuation allowance for all periods presented due to the uncertainty of realizing future tax benefits from our net operating loss carry-forwards and other deferred tax assets.
Inflation
Although historically not significant to our results of operations, financial condition and cash flows, we may experience inflationary pressures, primarily in personnel costs and with certain laboratory supplies. The extent of any future impacts from inflation on our business and our results of operations will be dependent upon how long elevated inflation levels persist and the extent to which the rate of inflation were to increase, if at all, neither of which we are able to predict. If elevated levels of inflation were to persist or if the rate of inflation were to accelerate, the purchasing power of our cash and cash equivalents may be diminished, our expenses could increase faster than anticipated and we may utilize our capital resources sooner than expected. Further, given the complexities of the reimbursement landscape in which we operate, our payors may be unwilling or unable to increase reimbursement rates to compensate for inflationary impacts. As such, the effects of inflation may adversely impact our results of operations, financial condition and cash flows.
Liquidity and Capital Resources
Our foreseeable material cash requirements as of September 30, 2024, are recognized as liabilities or generally are otherwise described in Note 6, “Commitments and Contingencies,” to our consolidated financial statements included elsewhere in this Report. Cash requirements are generally derived from our operating and investing activities including expenditures for working capital, human capital, business development, investments in intellectual property, and business combinations. Our office lease obligations, net of sublease payments, and contingent consideration obligations are further described in Note 6 and Note 3, respectively. Historically, we have not entered into any off-balance sheet arrangements. As of September 30, 2024 and December 31, 2023, we had unrecognized tax benefits totaling $2.3 million (see Note 2, “Income Taxes”).
Since formation, we have financed our operations primarily through the sale of our common stock, preferred stock and warrants. We have incurred operating losses and negative cash flows since inception and had an accumulated deficit of $317.0 million as of September 30, 2024. At September 30, 2024, we had $3.4 million of cash and cash equivalents. On October 4, 2024, we raised additional capital as discussed below. We expect to continue to incur operating losses and negative cash flows for the near future. Our expectation to generate operating losses and negative operating cash flows in the future and the need for additional funding to support our planned operations raise substantial doubt regarding our ability to continue as a going concern for a period of one year after the date that the financial statements are issued (see Note 1).
On April 3, 2023, we entered into an agreement with certain members of our Board of Directors, and several institutional and accredited investors, including Broadwood, our largest shareholder, relating to their purchase of an aggregate of up to 2,278,121 shares of our common stock at an offering price of $7.08 per share to board members and $6.03 per share to the other investors participating in the offering (see Note 7). The offering was intended to be priced at-the-market for purposes of complying with applicable Nasdaq Listing Rules. The aggregate gross proceeds from the offering were approximately $13.9 million before deducting offering expenses payable by us. We used approximately $1.1 million of the net proceeds to immediately redeem an aggregate of 1,064 shares of our Series A Redeemable Convertible Preferred Stock.
On April 15, 2024, we consummated the April 2024 Offering. The resulting net proceeds were approximately $9.9 million, after deducting offering expenses of $538,000 and deducting $5.4 million for the redemption of all remaining shares of our Series A Redeemable Convertible Preferred Stock. These net proceeds are inclusive of an investment from Bio-Rad (see Note 9), our global strategic partner. See Note 7, “Common Stock – April 2024 Offering,” to our consolidated financial statements included elsewhere in this Report for additional information.
On August 1, 2024, we filed a shelf registration statement on Form S-3, pursuant to which we registered for sale up to $100.0 million of any combination of our common stock, preferred stock, warrants and/or units from time to time and at prices and on terms that we may determine (the “Primary Shelf Registration Statement”). On August 9, 2024, we entered into a sales agreement with a sales agent, pursuant to which we may offer and sell from time to time up to an aggregate of $7.5 million of shares of our common stock, registered on the Primary Shelf Registration Statement, pursuant to the August 2024 Offering. As of September 30, 2024, we received net proceeds from the sale of such shares of approximately $17,000. See Note 7, “Common Stock – August 2024 Offering,” to our consolidated financial statements included elsewhere in this Report for additional information.
On October 4, 2024, we consummated the October 2024 Offering. The gross proceeds from the October 2024 Offering were approximately $10.2 million. After deducting placement agent fees and expenses and offering expenses payable by the Company of $795,000, the resulting net proceeds were approximately $9.4 million. See Note 12, “Subsequent Events,” to our consolidated financial statements included elsewhere in this Report for additional information.
We expect that our general operating expenses will be commensurate with the market opportunity as we continue to manage our available cash. Although we intend to market our diagnostic tests in the United States through our own sales force, we are also beginning to make marketing arrangements with distributors in other countries. We may also explore a range of other commercialization options in order to enter overseas markets and to reduce our capital needs and expenditures, and the risks associated with the timelines and uncertainty for attaining the Medicare reimbursement approvals that will be essential for the successful commercialization of additional cancer diagnostic tests. Those alternative arrangements could include marketing arrangements with other diagnostic companies through which we might receive a licensing fee and royalty on sales, or through which we might form a joint venture to market one or more tests and share in net revenues, in the United States or abroad.
On April 5, 2024, we entered into an agreement with Bio-Rad, our global strategic partner, to collaborate in the development and the commercialization of RUO and IVD kitted transplant products. On November 8, 2024, Oncocyte and Bio-Rad entered into a memorandum of understanding with respect to such agreement to establish additional activities to be performed by each party pursuant to such agreement. See Note 10, “Collaborative Arrangements,” to our consolidated financial statements included elsewhere in this Report for additional information.
In addition to sales and marketing expenses, we will incur expenses from leasing and improving our offices and laboratory facilities in Nashville, Tennessee. During the third quarter of 2023, we entered into a sublease arrangement for our main office in Irvine, California. In January 2024, we expanded our Nashville facility by adding one new office lease and renewing and extending our existing leases. During the second and third quarters of 2024, we added five financing leases for certain laboratory equipment to be used in our Nashville facility. See Note 6, “Commitments and Contingencies,” to our consolidated financial statements included elsewhere in this Report for additional leasing information.
We may need to meet significant cash payment or stock obligations to former Insight and Chronix shareholders in connection with our acquisition of those companies, as disclosed in Note 3 to the consolidated financial statements included elsewhere in this Report. To meet the future cash payment obligations, we may have to utilize cash on hand that would otherwise be available to us for other business and operational purposes, which could cause us to delay or reduce activities in the development and commercialization of our cancer tests.
We will need to continue to raise additional capital to finance our operations, including the development and commercialization of our diagnostic tests, and making payments that may become due under our obligations to former Chronix shareholders and former Insight shareholders, until such time as we are able to generate sufficient revenues to cover our operating expenses. Delays in our collaborative arrangement for the development and the commercialization of RUO and IVD kitted transplant products, or delays in obtaining regulatory approval to distribute our products for clinical use, or delays in the development of, or in obtaining reimbursement coverage from Medicare for DetermaIO and other future laboratory tests that we may develop or acquire, could prevent us from raising sufficient additional capital to finance the completion of development and commercial launch of those tests. Investors may be reluctant to provide us with capital until our tests are approved for reimbursement by Medicare or reimbursement by private healthcare insurers or healthcare providers, or until we begin generating significant amounts of revenue from performing those tests.
The unavailability or inadequacy of financing or revenues to meet future capital needs could force us to modify, curtail, delay, or suspend some or all aspects of our planned operations. Sales of additional equity securities could result in the dilution of the interests of our shareholders. We cannot assure that adequate long-term financing will be available on favorable terms, if at all.
See Note 1 and Note 7 to our consolidated financial statements included elsewhere in this Report for additional information about our going concern discussion and equity offerings, respectively.
Cash Used in Operations
During the nine months ended September 30, 2024, our total research and development expenses were $7.6 million, our sales and marketing expenses were $2.7 million, and our general and administrative expenses were $7.6 million. We also incurred $250,000 in total cost of revenues, including $66,000 amortization of intangible expenses. Consolidated net loss for the period was $27.2 million, and our consolidated net cash used in operating activities amounted to $15.4 million. Our cash used in operating activities during 2024 did not include the following noncash items: $1.0 million in depreciation and amortization expenses, $1.3 million in stock-based compensation, $110,000 in other equity compensation expenses, $9.4 million loss from change in fair value of contingent consideration, and $169,000 impairment loss on held for sale assets. Net changes in operating assets and liabilities for the period were $162,000 as an additional use of cash.
During the nine months ended September 30, 2023, our total research and development expenses were $6.7 million, our sales and marketing expenses were $2.2 million, and our general and administrative expenses were $9.4 million. We also incurred $659,000 in total cost of revenues, including $66,000 amortization of intangible expenses. Consolidated net loss for the period was $11.8 million, and our consolidated net cash used in operating activities amounted to $18.9 million. Our cash used in operating activities during 2023 did not include the following noncash items: $1.4 million in depreciation and amortization expenses, $2.3 million in stock-based compensation, $16.9 million gain from change in fair value of contingent consideration, $6.8 million loss from asset impairments, $1.5 million loss related to discontinued operations, $1.3 million loss on disposal and held for sale assets, $108,000 in other equity compensation expenses, and $8,000 in unrealized gain on marketable equity securities. Net changes in operating assets and liabilities for the period were $3.5 million as an additional use of cash.
Cash Used in Investing Activities
During the nine months ended September 30, 2024, net cash used in investing activities was $302,000 from cash paid for construction in progress and purchase of furniture and equipment.
During the nine months ended September 30, 2023, net cash used in investing activities was $1.0 million primarily from cash sold in discontinued operations, partially offset by proceeds from the sale of equipment.
Cash Provided by Financing Activities
During the nine months ended September 30, 2024, net cash provided by financing activities was $9.6 million from $15.1 million of net cash proceeds from the April 2024 Offering and the August 2024 Offering, partially offset by the redemption of our remaining Series A Preferred Stock of $5.4 million and repayments of financing lease obligations of $119,000.
During the nine months ended September 30, 2023, net cash provided by financing activities was $12.2 million from $13.4 million of net cash proceeds from the sale of shares of common stock, partially offset by the partial redemption of Series A Preferred Stock of $1.1 million and repayments of financing lease obligations of $87,000.
Critical Accounting Estimates
Our consolidated financial statements are prepared in conformity with GAAP. In preparing these financial statements, we make assumptions, judgments and estimates that involve a significant level of estimation uncertainty and have had or are reasonably likely to have a material impact on our financial condition or results of operations. We base our assumptions, judgments and estimates on historical experience and various other factors that we believe to be reasonable under the circumstances. Actual results could differ materially from these estimates under different assumptions or conditions. On a regular basis, we evaluate our assumptions, judgments and estimates and make changes accordingly.
We believe that of the significant accounting policies discussed in Note 2 to our consolidated financial statements included elsewhere in this Report, the following accounting policies involve a significant level of estimation uncertainty and require our most difficult, subjective or complex assumptions, judgments and estimates:
•Going Concern Assessment;
•Contingent Consideration Liabilities;
•Impairment of Long-Lived Assets;
•Revenue Recognition and Allowance for Credit Losses;
•Stock-Based Compensation; and
Going Concern Assessment
We assess going concern uncertainty in our consolidated financial statements to determine if we have sufficient cash and cash equivalents on hand and working capital, including available loans or lines of credit, if any, to operate for a period of at least one year from the date our consolidated financial statements are issued (the “look-forward period”). As part of this assessment, based on conditions that are known and reasonably knowable to us, we consider various scenarios, forecasts, projections and estimates, and we make certain key assumptions, including the timing and nature of projected cash expenditures or programs, and our ability to delay or curtail those expenditures or programs, if necessary, among other factors. Based on this assessment, as necessary or applicable, we make certain assumptions around implementing curtailments or delays in the nature and timing of programs and expenditures to the extent we deem probable those implementations can be achieved and we have the proper authority to execute them within the look-forward period. For additional information, refer to Note 1 to our consolidated financial statements included elsewhere in this Report.
Contingent Consideration Liabilities
Contingent consideration is estimated and recorded at fair value as of the acquisition date as part of the total consideration transferred. Contingent consideration is an obligation of the acquirer to transfer additional assets or equity interests to the selling shareholders in the future if certain future events occur or conditions are met, such as the attainment of product development milestones. Contingent consideration also includes additional future payments to selling shareholders based on achievement of components of earnings, such as “earn-out” provisions or percentage of future revenues, including royalties paid to the selling shareholders based on a percentage of certain revenues generated.
The fair value of milestone-based contingent consideration was determined using a scenario analysis valuation method which incorporates our assumptions with respect to the likelihood of achievement of the milestones, as defined in the merger agreements, credit risk, timing of the contingent consideration payments and a risk-adjusted discount rate to estimate the present value of the expected payments, all of which require significant management judgment and assumptions. Since the contingent consideration payments are based on nonfinancial, binary events, management believes the use of the scenario analysis method is appropriate.
The fair value of royalty or revenue share-based contingent consideration was determined using a single scenario analysis method to value those payments. The single scenario method incorporates our assumptions with respect to specified future revenues generated over their respective useful lives, credit risk, and a risk-adjusted discount rate to estimate the present value of the expected royalty payments, all of which require significant management judgment and assumptions. Since the royalty-based contingent consideration payments are based on future revenues and linear payouts, management believes the use of the single scenario method is appropriate.
The fair value of contingent consideration after the acquisition date is reassessed by us as changes in circumstances and conditions occur, with the subsequent change in fair value recorded in our consolidated statements of operations. Changes in key assumptions can materially affect the estimated fair value of contingent consideration liabilities and, accordingly, the resulting gain or loss that we record in our consolidated financial statements. During the nine months ended September 30, 2024 and 2023, we recorded a loss of $9.4 million and a gain of $16.9 million, respectively, related to the fair value of contingent consideration. As of September 30, 2024 and December 31, 2023, contingent consideration liabilities were $49.3 million and $39.9 million, respectively. For additional information, refer to Note 3 to our consolidated financial statements included elsewhere in this Report.
Intangible Assets
We consider various factors and risks for potential impairment of IPR&D intangible assets, including the current legal and regulatory environment and the competitive landscape. Adverse clinical trial results, significant delays or inability to obtain LCD from the Centers for Medicare and Medicaid Services for Medicare reimbursement for a diagnostic test, the inability to bring a diagnostic test to market and the introduction or advancement of competitors’ diagnostic tests could result in partial or full impairment of the related intangible assets. Consequently, the eventual realized value of the IPR&D project may vary from its fair value at the date of acquisition, and IPR&D impairment charges may occur in future periods. During the period between completion or abandonment, the IPR&D assets will not be amortized but will be tested for impairment on an annual basis and between annual tests if we become aware of any events occurring or changes in circumstances that would indicate a reduction in the fair value of the IPR&D projects below their respective carrying amounts.
During the first quarter of 2023, due to changes in management and our economic condition, management shifted our business strategy to direct efforts on fewer studies and to transition from tests that are laboratory developed tests (“LDTs”) to RUO sales. Due to the change in strategy, our long range plan forecasts were updated and anticipated future benefits derived from our assets. The change in strategy represent a significant indicator for change in value of our long-lived assets. The original IPR&D balances were reassessed based on the updated long range plan, using the multi-period excess earnings method approach, the results of the valuation noted that the carrying value of certain IPR&D intangible assets was greater than the fair market value. Accordingly, we recorded an impairment of approximately $5.0 million as of March 31, 2023. We have not recorded any additional impairment adjustments as of September 30, 2024. For additional information, refer to Note 5 to our consolidated financial statements included elsewhere in this Report.
Impairment of Long-Lived Assets
We assess the impairment of long-lived assets, which consists primarily of long-lived intangible assets, right-of-use assets, and machinery and equipment, whenever events or changes in circumstances indicate that such assets might be impaired and the carrying value may not be recoverable. When such events or changes in circumstances are present, we estimate the future cash flows expected to result from the use of the asset (or asset group) and its eventual disposition. If the sum of the expected undiscounted future cash flows is less than the carrying amount, we recognize an impairment based on the fair value of such assets. During the nine months ended September 30, 2024 and 2023, we recognized impairment losses on held for sales assets of $169,000 and $1.3 million, respectively. For additional information, refer to Note 2, “Assets Held for Sale and Discontinued Operations,” to our consolidated financial statements included elsewhere in this Report.
Revenue Recognition and Allowance for Credit Losses
Pharma Services revenue
Pharma Services are generally performed under individual scope of work (“SOW”) arrangements or license agreements (together with SOW the “Pharma Services Agreements”) with specific deliverables defined by the customer. Pharma Services are performed on a (i) time and materials basis or (ii) per test completed basis. Upon completion of the service to the customer in accordance with a Pharma Services Agreement, we have the right to bill the customer for the agreed upon price (either on a per test or per deliverable basis) and recognizes Pharma Service revenue at that time. Insight identifies each sale of its Pharma Service offering as a single performance obligation. Chronix identifies the processing of test samples as a separate performance obligation (considered a series) within license agreements with customers. Completion of the service and satisfaction of the performance obligation is typically evidenced by access to the report or test made available to the customer or any other form or applicable manner of delivery defined in the Pharma Services Agreements. However, for certain SOWs under which work is performed pursuant to the customer’s highly customized specifications, we have the enforceable right to bill the customer for work completed, rather than upon completion of the SOW. For those SOWs, we recognize revenue over a period during which the work is performed using a formula that accounts for expended efforts, generally measured in labor hours, as a percentage of total estimated efforts for the completion of the SOW. As performance obligations are satisfied under the Pharma Services Agreements, any amounts earned as revenue and billed to the customer are included in accounts receivable.
We establish an allowance for credit losses based on the evaluation of the collectability of its Pharma Services accounts receivables after considering a variety of factors, including the length of time receivables are past due, significant events that may impair the customer’s ability to pay, such as a bankruptcy filing or deterioration in the customer’s operating results or financial position, reasonable and supportable forecast that affect the collectability of the reported amount, and historical experience. We continuously monitor collections and payments from customers and maintains a provision for estimated credit losses and uncollectible accounts, if any, based upon its historical experience and any specific customer collection issues that have been identified. Amounts determined to be uncollectible are written off against the credit loss reserve accounts. As of September 30, 2024 and December 31, 2023, we had an allowance for credit losses of $2,000 and $5,000, respectively, related to Pharma Services.
Laboratory Developed Test Services
Although we have billed a list price for all tests ordered and completed for all payer types, we consider constraints on the variable consideration when recognizing revenue for DetermaRx. Because DetermaRx is a novel test and there are no current reimbursement arrangements with third-party payers other than Medicare, the transaction price represents variable consideration. Application of the constraint for variable consideration is an area that requires significant judgment. For all payers other than Medicare, we must consider the novelty of the test, the uncertainty of receiving payment, or being subject to claims for a refund, from payers with whom it does not have a sufficient payment collection history or contractual reimbursement agreements. Accordingly, for those payers, we have recognized revenue upon payment because it has had insufficient history to reliably estimate payment patterns.
We maintained an allowance for credit losses related to Laboratory Developed Test Services at an amount we estimated to be sufficient to provide adequate protection against losses resulting from extending credit to our customers. We based this allowance, in the aggregate, on historical collection experience, age of receivables and general economic conditions, as well as specific identification of uncollectible accounts. We initially established an allowance in 2022 in connection with remaining Medicare and Medicare Advantage account balances and continued to add to the allowance as appropriate. In the first quarter of 2023, in connection with the adoption of the new current expected credit loss model, the Company determined that the Medicare and Medicare Advantage accounts receivable net balance of approximately $1.4 million was uncollectible and should therefore be written-off as of the adoption date, January 1, 2023. As of September 30, 2024 and December 31, 2023, we had no receivables nor allowance for credit losses related to Laboratory Developed Test Services.
Stock-Based Compensation
We recognize compensation expense related to share-based payment awards made to employees, board directors and other non-employees based on estimated fair values. We estimate the fair value of stock-based payment awards on the grant date and recognize the resulting fair value over the requisite service period on a straight-line basis. For stock-based awards that vest only upon the attainment of one or more performance goals, compensation cost is recognized if and when we determine that it is probable that the performance condition or conditions will be, or have been, achieved. For grants with market-based and time-based vesting conditions, the fair value is estimated using the Monte Carlo simulation model, which includes the estimated period to achievement of the performance and market conditions, which are subject to the achievement of the market-based goals established by us and continued employment. We utilize the Black-Scholes option pricing model for determining the fair value of standard time-based stock options. Our determination of fair value of share-based payment awards on the date of grant using an option pricing model is affected by our stock price as well as assumptions regarding a number of complex and subjective variables. These variables include, but are not limited to, expected stock price volatility over the term of the awards, and actual and projected employee stock option exercise behaviors. We estimate the expected volatility using our own stock price volatility for a period equal to the expected term of the options. The expected term of options granted is based on our own experience. The risk-free rate is based on the U.S. Treasury rates in effect during the corresponding period of grant. Key inputs and assumptions may change as we continue to develop our own company estimates, experience and key inputs including our expected term, and stock price volatility based on the trading history of our stock in the public market. Changes in these subjective assumptions can materially affect the estimated value of equity grants and the stock-based compensation that we record in our consolidated financial statements. During the nine months ended September 30, 2024 and 2023, we recognized total stock-based compensation of $1.3 million and $2.3 million, respectively. For additional information, refer to Note 8 to our consolidated financial statements included elsewhere in this Report.
Income Taxes
We account for income taxes in accordance with ASC 740, Income Taxes, which prescribes the use of the asset and liability method, whereby deferred tax asset or liability account balances are calculated at the balance sheet date using current tax laws and rates in effect. The provision for income taxes for interim periods is determined using an estimated annual effective tax rate in accordance with ASC 740-270, Income Taxes, Interim Reporting. Valuation allowances are established when necessary to reduce deferred tax assets when it is more-likely-than-not that a portion or all of the deferred tax assets will not be realized. Our judgments regarding future taxable income may change over time due to changes in market conditions, changes in tax laws, tax planning strategies or other factors. If our assumptions and consequently our estimates change in the future, the valuation allowance may be increased or decreased, which may have a material impact on our statements of operations.
The guidance also prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not sustainable upon examination by taxing authorities. We will recognize accrued interest and penalties, if any, related to unrecognized tax benefits as income tax expense. No amounts were accrued for the payment of interest and penalties as of the financial statement periods presented herein. We account for uncertain tax positions by assessing all material positions taken in any assessment or challenge by relevant taxing authorities. We are currently unaware of any tax issues under review. Refer to Note 2, “Income Taxes,” to our consolidated financial statements included elsewhere in this Report.
